An interventional study of EOXY device and Gold standard oximeter in Healthy, sponsored by BioSerenity. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-12.
Sponsored by BioSerenity · Not applicable, Interventional, and Other
The purpose of the study is to test the performance and safety of the Bioserenity pulse oxymeter EOXY. For that, and in agreement with ISO60601-2-61 norm and FDA regulation, measures of heart rate, with a gold-standard, and SaO2 measures generated by blood samples will be compared with Sp02 and heart rate measures that are generated by our EOXY.
Thirteen healthy subjects will participate in the study in total. Three subjects will be enrolled during a primary phase .They will participate at a secondary phase as well as ten others subjects. The purpose of the primary phase is to test the body area where the measurement can be done. The purpose of the secondary phase is to measure SpO2 and HR in desaturation conditions.
The primary objective is to evaluate and document the SpO2 accuracy of the pulse oximeter equipment, evaluating the performance of the device compared to invasive method blood sampling (SaO2) by CO-Oximeter in healthy subjects during invasive controlled desaturation study at different ranges (100 % to 70% SaO2).
Subject safety during desaturation and saturation period, will be evaluated by reviewing vital sign: heart rate (HR) continuously and blood pressure/temperature between each desaturation plateau.
There are two secondaries objectives, the measurement of the variation of the fraction of inspired oxygen (FiO2), and the validation of the algorithm for data review and analysis.
For the study primary phase, the purpose of this phase is to test the body area where the SpO2 is better detected and define 3 measurement areas. For this, three healthy volunteers will be placed in normal O2 saturation, the SpO2 will be measured using the Bioserenity oximeter (noninvasive method) and will be compared to a gold-standard oximeter CE-marked. The investigator will determine the best area in the body where the SpO2 could be taken for the following subjects.
During a second phase, the measurement of Sp02 and HR with EOXY, will be performed in O2 saturation conditions up to 100% and then in desaturation by plateau from 100 % to 70%. 3 EOXY pulse oximeter recorded the SpO2 at the same time in 3 different areas of the body. As required by the standard, Sp02 measures will be simultaneously compared to SaO2 values measured by blood sampling taken from an indwelling arterial catheter. The HR obtained with EOXY will be compared simultaneously to a gold standard oximeter CE-marked.
As the example in the standard, it was choosen to do the test on the 70-100% range, with 5 plateaus (100%-97%, 97%-92%, 92%-85%, 84%-78%, 77%-70%) and to collect five Sp02 and Sa02 values (blood samples) and five HR measures, per plateau, for each of 13 subjects.
The desaturation will be controlled thanks' the FiO2 measures, that should allow to bring subjects near target levels of desaturation plateau.
Exclusion Criteria:
Heart rate and SPO2 measures provided from EOXY device Heart rate measures provided from gold standard oximeter. SaO2 measures provided from blood sampling There is only one arm: all subjects have simultaneously three interventions (as required in the European standard ISO 80601-2-61), to qualify a pulse oximeter
Device: EOXY device · Device: Gold standard oximeter · Procedure: SaO2 sampling
Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
Percentage SPO2 Accuracy Root-Mean Square (ARMS) at Forehead Position
For each desaturation plateau, SpO2 ARMS are calculated by the difference between the investigational pulse oximeter SpO2 measurement and the co-oximeter's SaO2 measurements
Time frame: 1 day
Percentage SPO2 Accuracy Root-Mean Square (ARMS) at Torso Position
For each desaturation plateau, SpO2 ARMS (Accuracy Root-Mean Square) are calculated by the difference between the investigational pulse oximeter SpO2 measurement and the co-oximeter's SaO2 measurements
Time frame: 1 day
Percentage SPO2 Accuracy Root-Mean Square (ARMS) at BACK Position
For each desaturation plateau, SpO2 ARMS are calculated by the difference between the investigational pulse oximeter SpO2 measurement and the co-oximeter's SaO2 measurements
Time frame: 1 day
HR Accuracy Root-Mean Square (ARMS) at Forehead Position
For each desaturation plateau, HR ARMS are calculated by the difference between the investigational pulse oximeter HR measurement and the HR gold standard measurements
Time frame: 1 day
Percentage of HR Accuracy Root-Mean Square (ARMS) at TORSO Position
For each desaturation plateau, HR ARMS are calculated by the difference between the investigational pulse oximeter HR measurement and the HR gold standard measurements
Time frame: 1 day
Percentage of HR Accuracy Root-Mean Square (ARMS) at BACK Position
For each desaturation plateau, HR ARMS are calculated by the difference between the investigational pulse oximeter HR measurement and the HR gold standard measurements
Time frame: 1 day
| Milestone | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
For each desaturation plateau, SpO2 ARMS are calculated by the difference between the investigational pulse oximeter SpO2 measurement and the co-oximeter's SaO2 measurements
| percentage of ARMS (accuracy) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| Overall range 70-100% of O2 | 3.91 |
| 97-100% of O2 | 3.08 |
| 97-92% of O2 | 3.36 |
| 92-85% of O2 | 2.85 |
| 84-78% of O2 | 3.48 |
| 77-70% of O2 | 6.21 |
For each desaturation plateau, SpO2 ARMS (Accuracy Root-Mean Square) are calculated by the difference between the investigational pulse oximeter SpO2 measurement and the co-oximeter's SaO2 measurements
| percentage of ARMS (accuracy) | EOXY Device and Gold Standard Oximter and SaO2 Measures |
|---|---|
| Overall range 70-100% of O2 | 11.14 |
| 97-100% of O2 | 12.99 |
| 97-92% of O2 | 12.51 |
| 92-85% of O2 | 9.91 |
| 84-78% of O2 | 7.31 |
| 77-70% of O2 | 10.76 |
For each desaturation plateau, SpO2 ARMS are calculated by the difference between the investigational pulse oximeter SpO2 measurement and the co-oximeter's SaO2 measurements
| percentage of ARMS (accuracy) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| Overall range 70-100% of O2 | 6.02 |
| 97-100% of O2 | 7.09 |
| 97-92% of O2 | 6.63 |
| 92-85% of O2 | 6.57 |
| 84-78% of O2 | 5.06 |
| 77-70% of O2 | 3.96 |
For each desaturation plateau, HR ARMS are calculated by the difference between the investigational pulse oximeter HR measurement and the HR gold standard measurements
| percentage of ARMS (accuracy) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| Overall range 70-100% of O2 | 12.2 |
| 97-100% of O2 | 10.0 |
| 97-92% of O2 | 11.7 |
| 92-85% of O2 | 11.5 |
| 84-78% of O2 | 14.3 |
| 77-70% of O2 | 13.0 |
For each desaturation plateau, HR ARMS are calculated by the difference between the investigational pulse oximeter HR measurement and the HR gold standard measurements
| percentage of ARMS (accuracy) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| Overall range 70-100% of O2 | 32.1 |
| 97-100% of O2 | 30.8 |
| 97-92% of O2 | 31.5 |
| 92-85% of O2 | 31.5 |
| 84-78% of O2 | 30.4 |
| 77-70% of O2 | 36.5 |
For each desaturation plateau, HR ARMS are calculated by the difference between the investigational pulse oximeter HR measurement and the HR gold standard measurements
| percentage of ARMS (accuracy) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| Overall range 70-100% of O2 | 21.1 |
| 97-100% of O2 | 22.3 |
| 97-92% of O2 | 24.6 |
| 92-85% of O2 | 19.2 |
| 84-78% of O2 | 19.1 |
| 77-70% of O2 | 20.6 |
Collected over 2 days for each subject (days of participation). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EOXY Device and Gold Standard Oximeter and SaO2 Measures | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
Healthy subjects (3 patients excluded reducing the number analyzed at 10)
| Age, Categorical(Participants) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 10 |
| >=65 years | 0 |
| Age, Continuous(years) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| Mean | 23.5 (19 to 35) |
| Sex: Female, Male(Participants) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| Female | 3 |
| Male | 7 |
| Race (NIH/OMB)(Participants) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 6 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | EOXY Device and Gold Standard Oximeter and SaO2 Measures |
|---|---|
| Belgium | 10 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioSerenity